 Suramin
"Suramin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
| Descriptor ID |
D013498
|
| MeSH Number(s) |
D02.455.426.559.847.638.555.750 D02.886.645.600.080.050.650.750 D04.615.638.555.750
|
| Concept/Terms |
Suramin Sodium- Suramin Sodium
- Sodium, Suramin
- Suramin, Hexasodium Salt
- Hexasodium Salt Suramin
- Salt Suramin, Hexasodium
|
Below are MeSH descriptors whose meaning is more general than "Suramin".
Below are MeSH descriptors whose meaning is more specific than "Suramin".
This graph shows the total number of publications written about "Suramin" by people in this website by year, and whether "Suramin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 | | 1995 | 1 | 1 | 2 | | 1996 | 4 | 1 | 5 | | 1997 | 1 | 1 | 2 | | 2002 | 2 | 0 | 2 | | 2004 | 2 | 0 | 2 | | 2008 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Suramin" by people in Profiles.
-
Cui H, Kamal Z, Ai T, Xu Y, More SS, Wilson DJ, Chen L. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. J Med Chem. 2014 Oct 23; 57(20):8340-57.
-
Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol. 2008 Jan; 63(1):61-71.
-
Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
-
Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
-
Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
-
Ryan CW, Vokes EE, Vogelzang NJ, Janisch L, Kobayashi K, Ratain MJ. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
-
Sima B, Weir BK, Macdonald RL, Zhang H. Extracellular nucleotide-induced [Ca2+]i elevation in rat basilar smooth muscle cells. Stroke. 1997 Oct; 28(10):2053-8; discussion 2059.
-
Soliven B, Dhand UK, Kobayashi K, Arora R, Martin B, Petersen MV, Janisch L, Vogelzang NJ, Vokes EE, Ratain MJ. Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve. 1997 Jan; 20(1):83-91.
-
Kobayashi K, Weiss RE, Vogelzang NJ, Vokes EE, Janisch L, Ratain MJ. Mineralocorticoid insufficiency due to suramin therapy. Cancer. 1996 Dec 01; 78(11):2411-20.
-
Kobayashi K, Vokes EE, Vogelzang NJ, Ratain MJ. Data modifications to phase I study of suramin. J Clin Oncol. 1996 Sep; 14(9):2623-4.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|